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Abstract
Poly(ADP-ribose)polymerase (PARP) is a nuclear enzyme which plays an important role in
regulating cell death and cellular responses to DNA repair. Pharmacological inhibitors of PARP are
being considered as treatment for cancer both in monotherapy as well as in combination with
chemotherapeutic agents and radiation, and were also reported to be protective against untoward
effects exerted by certain anticancer drugs.
Here we show that pharmacological inhibition of PARP with 3-aminobenzamide or PJ-34 dose-
dependently reduces VEGF-induced proliferation, migration and tube formation of human umbilical
vein endothelial cells in vitro.
These results suggest that treatment with PARP inhibitors may exert additional benefits in various
cancers and retinopathies by decreasing angiogenesis.
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Introduction
Poly(ADP ribose) polymerase (PARP), also known as poly(ADP ribose) synthetase (PARS),
is a family of abundant nuclear enzymes of eukaryotic cells that participates in the regulation
of DNA repair, gene transcription, cell cycle progression, chromatin function, genomic stability
and cell death [1;2]. Pharmacological inhibitors of PARP are recently being considered as
treatment for cancer both in monotherapy as well as in combination with chemotherapeutic
agents and radiation [2;3;4;5;6;7] and entering clinical development as cytoprotective agents
in cardiovascular diseases [2;4;8]. Angiogenesis is very important in the growth and metastasis
formation of a variety of tumors, and increased angiogenesis also contributes to the
development of blindness associated with diabetic retinopathy. In the present study we studied
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the effects of PARP inhibition with 3-AB and PJ-34 on VEGF-induced proliferation, migration
and tube formation of human umbilical vein endothelial cells in vitro.
Materials and Methods
Reagents
Human recombinant VEGF165 was purchased from R&D systems (Minneapolis, MN). PARP
inhibitor 3-aminobenzamide was obtained from Sigma, and PJ-34 was from Inotek
Pharmaceuticals (Boston, MA).
Cell Culture
Human umbilical vein endothelial cells (HUVEC) and endothelial cells growth medium
EGM™ were purchased from Cambrex, (Walkersville, MD) and cells were cultured in EGM™
medium according to manufacture’s instruction. Cells were grown in either 100 mm dishes or
6 well multi-dish chambers coated with 0.2 % gelatin. Cells were used within passages 3 to 7.
Prior to treatment, cells were acclimatized in endothelial basal medium containing 1% FBS
(Invitrogen, CA) 6 hrs and then treated.
Cell viability assays
Cells were grown in 96 well plates and treated with either aminobenzamide (3-AB) or PJ 34
with varying concentrations for 6 hrs in growth factor free medium containing 1 % FBS. Then
effects of the PARP inhibitors on cell viability were determined using commercially available
MTT assay (Promega, WI). Each experiment was repeated in triplicate and the entire set of
experiments was repeated three times.
Proliferation assay
Endothelial cells (5 X 103 ) cells were suspended in 100 μl of growth factor free medium
containing 1 % FBS and then treated with either VEGF 20 ng/ml alone or PARP inhibitors 3-
AB (0.5–6 mM) and PJ 34 (0.5–6 μM) and seeded on to 0.2 % gelatin coated 96 well plates
and allowed to proliferate for 24 hrs. Then BrdU labeling solution was added and incubated
further for 12 hrs. After the incubation, the effect of PARP inhibitors on VEGF induced
proliferation of the HUVECs was determined by the extent of BrdU incorporation using ELISA
kit following the protocol supplied by the manufacturer (Roche Diagnostics, IN). In brief, after
the incubation of cells with BrdU labeling solution, the medium was aspirated and the cells
were fixed and incubated with anti-BrdU antibody. After washing, the cells were incubated
with secondary antibody conjugated with horse radish peroxidase. Finally, the extent of BrdU
incorporation was determined colorimetrically at 450 nm. The treatments were performed in
triplicate and the experiment was repeated at least three times.
Migration assay
The migration assays were performed in a 24–well modified Boyden chamber as described
earlier [9]. In brief, 8 μm cell culture inserts (BD Biosciences) coated with 0.2 % gelatin
(Sigma) were placed over the bottom chamber containing 20 ng/ml VEGF as the chemo-
attractant. Growth factor free medium containing 1% FBS served as negative control. 3 X
104 cells were suspended in 150 μl in growth factor free medium containing 1% FBS. Then
the cells were pretreated with PARP inhibitors, for 30 min at 37°C in 5% CO2 incubator. Then
the HUVECs cell suspension was added to the upper chamber. After 8 hrs of incubation at 37°
C, the non-migrated cells on the upper surface of the filter were removed by gentle swabbing
with cotton tipped applicators. The cells that had migrated to the lower side of the chamber
were fixed with 100 % methanol for 15 min at room temperature. After complete drying, the
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cells were stained with 0.5 % Giemsa stain (Sigma). 3–4 fields per insert were counted using
10X objective using Olympus IX81 microscope. The assays were performed in triplicate.
In vitro angiogenesis assay
The effect of PARP inhibits on inhibiting the formation of tube-like structures on growth factor
reduced Matrigel (BD Biosciences) were performed as described earlier [9;10]. In brief, 96
well plates were coated with 50 μl of growth factor reduced Matrigel and allowed to solidify
at 37°C in 5% CO2. During the incubation for the solidification of Matrigel, the cells were
treated exactly as described as above and seeded on to the solidified matrix. After 12 hrs of
incubation at 37°C in 5% CO2, the medium was carefully aspirated and the cells were fixed
with 4% formaldehyde and the images were captured using Olympus IX81 microscope. The
tube length was quantified using the NIH Image J software. Results are represented as total
tube length (μm) for three photographic fields per experimental condition. Each treatment was
performed in duplicate and the set of experiment was independently repeated three times.
Statistical analysis
Values are represented as mean ± SD. The statistical significance of the data was analyzed
using students ‘t’ test. P < 0.05 was considered as significant.
Results
PARP inhibitors did not affect cell viability in HUVECs
As shown in Fig.1, and consistently with results of numerous previous studies ( [11;12;13];
reviewed in [1]) 3-AB (0.5–6 mM) and PJ-34 (0.5–6 μM) did not decrease cell viability in
HUVECs.
PARP inhibitors decrease VEGF- induced proliferation of HUVECs
As shown in Fig.2., VEGF enhanced the proliferation of HUVECs (measured by BrdU
incorporation assay) by 4 fold (P<0001 vs. control) and both 3-AB and PJ-34 significantly
inhibited the HUVECs proliferation in a dose dependent manner (P < 0.001 vs. VEGF). 3-AB
or PJ-34 alone had no effect on the proliferation of HUVECs (data not shown).
PARP inhibitors decrease VEGF- induced migration of HUVECs
As shown in Fig. 3, VEGF significantly enhanced the migration of HUVECs in the order of
~3 fold (P < 0.001 vs. control). 3-AB and PJ-34 elicited concentration dependent inhibition in
VEGF induced migration of HUVECs (Fig. 3A and B, P<0.001 vs. VEGF). On the other hand,
3-AB or PJ-34 by itself had no effect on migration and the results were comparable to that of
vehicle control (data not shown).
PARP inhibitors decrease VEGF-induced tube formation in vitro in HUVECs
When HUVECs were placed on growth factor reduced Matrigel, in the presence of VEGF 20
ng/ml, endothelial cells differentiate in to tube- like structures mimicking the neoangiogenesis
process in vivo (Fig. 4, P < 0.001 vs. control). When HUVECs were pretreated with 3-AB (0.5
– 6 mM) or PJ-34 (0.5 – 6.0 μM) and plated on to polymerized Matrigel, in the presence of
VEGF (20 ng/ml), both 3-AB and PJ-34 dose-dependently inhibited the tube formation of
HUVECs when compared with cells treated with VEGF alone (Fig. 4; P < 0.001 vs. VEGF).
Quantification of tube length revealed that VEGF enhanced the tube formation by ~3 fold when
compared to control cells and this was decreased by PARP inhibitors in dose-dependent
manner. PARP inhibitors alone had no effect on tube formation of HUVECs (data not shown).
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Discussion
Pharmacological inhibitors of PARP have been shown to decrease tumor growth and to restore
sensitivity of resistant tumors to methylating agents or topoisomerase I inhibitors (drugs
recently used for the treatment of various malignancies refractory to conventional
chemotherapy), and to increase the sensitivity of cancer cells to radiotherapy [3;4;5;6;7;14;
15;16;17;18;19;20;21;22]. The use of PARP inhibitors as anticancer agents exploits the fact
that the repair of certain types of antitumor-agent related cellular damage relies almost
exclusively on the functional integrity of PARP [3].
In the present study we demonstrate that pharmacological inhibition of PARP exerts
antiangiogenic effects by reducing VEGF-induced proliferation, migration and tube formation
of human umbilical vein endothelial cells in vitro. These results suggest that PARP inhibition
may exert additional beneficial effects by decreasing angiogenesis-dependent growth in certain
types of tumors and by inhibiting tumor metastasis formation. Interestingly, a semisynthetic
tetracycline antimicrobial antibiotic minocycline, which has recently been reported to have
potent PARP-1 inhibitory effects [23;24] also inhibits angiogenesis [25].
Antiangiogenetic potential of PARP inhibitors can further be exploited for the treatment of
diabetic retinopathy, where the pathologically increased angiogenesis is the major cause of
complications and blindness. PARP activation is also involved in the development of various
diabetic complications (reviewed in [26]) including retinopathy [27;28] and PARP inhibitors
exert protective effects against these pathologies [26].
Excitingly, PARP inhibitors were also reported to protect against nephrotoxicity of cisplatin
[29] and cardiotoxicity of doxorubicin [30;31], which cause oxidative/nitrosative stress and
consequent PARP overactivation and cell death. The cytoprotective effects of PARP inhibitors
comprise of inhibition of the pathological overactivation of PARP, and blockade of the cell
from entering into necrosis via over-utilization of cellular NAD+ pools and promotion of
cellular energetic failure [1;2].
Collectively, the present results suggest that treatment with PARP inhibitors may exert
additional benefits in various cancers and retinopathies by decreasing angiogenesis.
Acknowledgements
This study was supported by the Intramural Research Program of NIH/NIAAA (to P.P.). Dr. Pacher wants to dedicate
this work to his beloved mother Iren.
References
1. Virag L, Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol
Rev 2002;54:375–429. [PubMed: 12223530]
2. Jagtap P, Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev
Drug Discov 2005;4:421–40. [PubMed: 15864271]
3. Graziani G, Battaini F, Zhang J. PARP-1 inhibition to treat cancer, ischemia, inflammation. Pharmacol
Res 2005;52:1–4. [PubMed: 15911328]
4. Graziani G, Szabo C. Clinical perspectives of PARP inhibitors. Pharmacol Res 2005;52:109–18.
[PubMed: 15911339]
5. Tentori L, Leonetti C, Scarsella M, Muzi A, Mazzon E, Vergati M, Forini O, Lapidus R, Xu W, Dorio
AS, Zhang J, Cuzzocrea S, Graziani G. Inhibition of poly(ADP-ribose) polymerase prevents
irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon
carcinoma. Faseb J 2006;20:1709–11. [PubMed: 16809434]
Rajesh et al. Page 4
Biochem Biophys Res Commun. Author manuscript; available in PMC 2007 November 17.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
6. De Soto JA, Wang X, Tominaga Y, Wang RH, Cao L, Qiao W, Li C, Xu X, Skoumbourdis AP,
Prindiville SA, Thomas CJ, Deng CX. The Inhibition and Treatment of Breast Cancer with Poly (ADP-
ribose) Polymerase (PARP-1) Inhibitors. Int J Biol Sci 2006;2:179–85. [PubMed: 16810332]
7. De Soto JA, Deng CX. PARP-1 inhibitors: are they the long-sought genetically specific drugs for
BRCA1/2-associated breast cancers? Int J Med Sci 2006;3:117–23. [PubMed: 16906222]
8. Pacher P, Schulz R, Liaudet L, Szabo C. Nitrosative stress and pharmacological modulation of heart
failure. Trends Pharmacol Sci 2005;26:302–10. [PubMed: 15925705]
9. Cattaneo MG, Pola S, Francescato P, Chillemi F, Vicentini LM. Human endostatin-derived synthetic
peptides possess potent antiangiogenic properties in vitro and in vivo. Exp Cell Res 2003;283:230–6.
[PubMed: 12581742]
10. Rajesh M, Kolmakova A, Chatterjee S. Novel role of lactosylceramide in vascular endothelial growth
factor-mediated angiogenesis in human endothelial cells. Circ Res 2005;97:796–804. [PubMed:
16151023]
11. Garcia Soriano F, Virag L, Jagtap P, Szabo E, Mabley JG, Liaudet L, Marton A, Hoyt DG, Murthy
KG, Salzman AL, Southan GJ, Szabo C. Diabetic endothelial dysfunction: the role of poly(ADP-
ribose) polymerase activation. Nat Med 2001;7:108–13. [PubMed: 11135624]
12. Soriano FG, Pacher P, Mabley J, Liaudet L, Szabo C. Rapid reversal of the diabetic endothelial
dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase. Circ Res 2001;89:684–
91. [PubMed: 11597991]
13. Jagtap P, Soriano FG, Virag L, Liaudet L, Mabley J, Szabo E, Hasko G, Marton A, Lorigados CB,
Gallyas F Jr, Sumegi B, Hoyt DG, Baloglu E, VanDuzer J, Salzman AL, Southan GJ, Szabo C. Novel
phenanthridinone inhibitors of poly (adenosine 5′-diphosphate-ribose) synthetase: potent
cytoprotective and antishock agents. Crit Care Med 2002;30:1071–82. [PubMed: 12006805]
14. Delaney CA, Wang LZ, Kyle S, White AW, Calvert AH, Curtin NJ, Durkacz BW, Hostomsky Z,
Newell DR. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel
poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin
Cancer Res 2000;6:2860–7. [PubMed: 10914735]
15. Tentori L, Portarena I, Vernole P, De Fabritiis P, Madaio R, Balduzzi A, Roy R, Bonmassar E, Graziani
G. Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-
ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair
components. Cancer Chemother Pharmacol 2001;47:361–9. [PubMed: 11345654]
16. Canan Koch SS, LH Thoresen, Tikhe JG, Maegley KA, Almassy RJ, Li J, Yu XH, Zook SE, Kumpf
RA, Zhang C, Boritzki TJ, Mansour RN, Zhang KE, Ekker A, Calabrese CR, Curtin NJ, Kyle S,
Thomas HD, Wang LZ, Calvert AH, Golding BT, Griffin RJ, Newell DR, Webber SE, Hostomsky
Z. Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer
chemopotentiating activity: design, synthesis, and X-ray cocrystal structure. J Med Chem
2002;45:4961–74. [PubMed: 12408707]
17. Tentori L, Portarena I, Bonmassar E, Graziani G. Combined effects of adenovirus-mediated wild-
type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair
deficient and non-proliferating tumor cells. Cell Death Differ 2001;8:457–69. [PubMed: 11423906]
18. Calabrese CR, Batey MA, Thomas HD, Durkacz BW, Wang LZ, Kyle S, Skalitzky D, Li J, Zhang
C, Boritzki T, Maegley K, Calvert AH, Hostomsky Z, Newell DR, Curtin NJ. Identification of potent
nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological
studies. Clin Cancer Res 2003;9:2711–8. [PubMed: 12855651]
19. Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, Durkacz BW,
Hostomsky Z, Kumpf RA, Kyle S, Li J, Maegley K, Newell DR, Notarianni E, Stratford IJ, Skalitzky
D, Thomas HD, Wang LZ, Webber SE, Williams KJ, Curtin NJ. Anticancer chemosensitization and
radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer
Inst 2004;96:56–67. [PubMed: 14709739]
20. Curtin NJ, Wang LZ, Yiakouvaki A, Kyle S, Arris CA, Canan-Koch S, Webber SE, Durkacz BW,
Calvert HA, Hostomsky Z, Newell DR. Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361,
restores sensitivity to temozolomide in mismatch repair-deficient cells. Clin Cancer Res
2004;10:881–9. [PubMed: 14871963]
Rajesh et al. Page 5
Biochem Biophys Res Commun. Author manuscript; available in PMC 2007 November 17.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
21. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ,
Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose)
polymerase. Nature 2005;434:913–7. [PubMed: 15829966]
22. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ,
Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A. Targeting the DNA repair
defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917–21. [PubMed:
15829967]
23. Alano CC, Kauppinen TM, Valls AV, Swanson RA. Minocycline inhibits poly(ADP-ribose)
polymerase-1 at nanomolar concentrations. Proc Natl Acad Sci U S A 2006;103:9685–90. [PubMed:
16769901]
24. Szabo C, Pacher P, Swanson A. Novel modulators of poly(ADP-ribose) polymerase. Trends in
Pharmacological Sciences. 2006In press
25. Tamargo RJ, Bok RA, Brem H. Angiogenesis inhibition by minocycline. Cancer Res 1991;51:672–
5. [PubMed: 1702361]
26. Pacher P, Szabo C. Role of poly(ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic
complications: endothelial dysfunction, as a common underlying theme. Antioxid Redox Signal
2005;7:1568–80. [PubMed: 16356120]
27. Zheng L, Szabo C, Kern TS. Poly(ADP-ribose) polymerase is involved in the development of diabetic
retinopathy via regulation of nuclear factor-kappaB. Diabetes 2004;53:2960–7. [PubMed: 15504977]
28. Obrosova IG, Minchenko AG, Frank RN, Seigel GM, Zsengeller Z, Pacher P, Stevens MJ, Szabo C.
Poly(ADP-ribose) polymerase inhibitors counteract diabetes- and hypoxia-induced retinal vascular
endothelial growth factor overexpression. Int J Mol Med 2004;14:55–64. [PubMed: 15202016]
29. Racz I, Tory K, Gallyas F Jr, Berente Z, Osz E, Jaszlits L, Bernath S, Sumegi B, Rabloczky G, Literati-
Nagy P. BGP-15 - a novel poly(ADP-ribose) polymerase inhibitor - protects against nephrotoxicity
of cisplatin without compromising its antitumor activity. Biochem Pharmacol 2002;63:1099–111.
[PubMed: 11931842]
30. Pacher P, Liaudet L, Bai P, Virag L, Mabley JG, Hasko G, Szabo C. Activation of poly(ADP-ribose)
polymerase contributes to development of doxorubicin-induced heart failure. J Pharmacol Exp Ther
2002;300:862–7. [PubMed: 11861791]
31. Pacher P, Liaudet L, Mabley JG, Cziraki A, Hasko G, Szabo C. Beneficial effects of a novel ultrapotent
poly(ADP-ribose) polymerase inhibitor in murine models of heart failure. Int J Mol Med
2006;17:369–75. [PubMed: 16391839]
Rajesh et al. Page 6
Biochem Biophys Res Commun. Author manuscript; available in PMC 2007 November 17.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig.1. PARP inhibitors did not affect cell viability of HUVECs
Cells were grown in 96 well plates and treated with either aminobenzamide (3-AB) or PJ-34
with varying concentrations as indicated for 6 hrs. Then the cytotoxic effects of the PARP
inhibitors were determined using commercially available MTT assay, n = 3.
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Fig.2. PARP inhibitors decrease VEGF-induced proliferation of HUVECs
HUVECs were treated with either VEGF alone or with PARP inhibitors as indicated and the
proliferation of HUVECs were assed by measuring the rate of BrdU incorporation by ELISA
kit colorimetricaly at 450 nm. * P < 0.001 vs. control ; # P < 0.001 vs. VEGF ; ¶ P < 0.001 vs.
VEGF ; † P < 0.001 vs. VEGF ; n =3.
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Fig.3. PARP inhibitors attenuate VEGF-induced migration of HUVECs
Cells were treated with either VEGF or PARP inhibitors as indicated and migration assays
were performed using Boyden chamber.
(A) Depicts the representative images of HUVECs migrated in response to treatment with either
vehicle control, 20 ng/ml VEGF alone, 6 mM 3-AB + VEGF or 6 μM PJ–34 respectively.
(B) Shows the quantification of data for cell migration in response to treatments. * P < 0.001
vs. control; # P < 0.001 vs. VEGF ; ¶ P < 0.001 vs. VEGF ; † P < 0.001 vs. VEGF ; n =3.
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Fig.4. PARP inhibitors inhibit VEGF-induced tube formation in vitro
HUVECs were treated with either VEGF or PARP inhibitors+VEGF and an in vitro
angiogenesis assays were performed using growth factor reduced Matrigel as described in the
Methods section.
(A) Depicts the representative images of tube formation of cells treated with either VEGF alone
or with 3-AB (6 mM) or PJ-34 (6 μM) showing the maximum inhibitory effect.
(B) Shows the quantitative data for the tube lengths in cells treated as indicated in the figure.
* P < 0.001 vs. control ; # P < 0.001 vs. VEGF ; ¶ P < 0.001 vs. VEGF ; † P < 0.001 vs. VEGF ;
n =3.
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